Sol-Gel Technologies (4SG) Price & Analysis

0 Followers

4SG Stock Chart & Stats

€57.00

-€3.00(-4.29%)

At close: Jul 28 4:00 PM EDT

€57.00

-€3.00(-4.29%)

Day’s Range― - ―

52-Week Range€19.20 - €82.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€186.05M

Enterprise Value€195.32

Total Cash (Recent Filing)€30.47M

Total Debt (Recent Filing)€1.39M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

Nov 05, 2026

EPS Estimate

-1.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.97

Shares Outstanding3,273,999

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.46

Price to Book (P/B)5.15

Price to Sales (P/S)6.06

P/FCF Ratio426.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€169.49

Price Target Upside197.35% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-6.43

Revenue Forecast (FY)€403.91K

Bulls Say, Bears Say

Bulls Say

Cash RunwayThe cash and marketable securities balance provides a substantial operating runway through the expected clinical readout and beyond. This reduces near-term financing pressure, supports continued development of the pipeline, and gives management flexibility to pursue a focused launch strategy.

Late-stage Clinical ProgressProgress in the pivotal Gorlin syndrome trial is a meaningful potential catalyst because it could move the lead program toward commercialization. Low reported dropout and a defined late-2026 readout indicate execution against a key development milestone, though efficacy remains pending.

Pipeline ExpansionExpanding patidegib into additional basal cell carcinoma settings and extending the Gorlin-focused pipeline can broaden the company’s future addressable market. Multiple capital-efficient studies create several paths for value creation beyond the initial indication if clinical results support advancement.

Bears Say

Revenue VolatilityThe sharp year-over-year revenue decline demonstrates that reported sales can be materially affected by non-recurring IP-related income rather than repeatable product demand. Such volatility makes the commercial trajectory harder to assess and increases dependence on marketed products and future launches.

Persistent UnprofitabilityContinued net and operating losses show that the business has not yet converted its products and development activities into sustainable earnings. Persistent losses can limit internally funded investment, keep results dependent on financing or partnerships, and weaken resilience if commercialization takes longer.

Eroding Equity BaseThe shrinking equity base indicates that cumulative losses have consumed a substantial portion of shareholder capital despite low debt. While leverage remains conservative, continued erosion would reduce financial flexibility and make sustained profitability increasingly important for funding future development.

Sol-Gel Technologies News

Sol-Gel Therapeutics: Steady SGT-610 Execution and Capital-Efficient Growth Strategy Drive Price Target Increase to $195 and Support Buy Rating

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Sol-Gel Technologies today and set a price target...

24d ago

SLGL

Sol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout

The latest announcement is out from Sol-Gel Technologies ( ($SLGL) ). On August 20, 2026, Sol-Gel Technologies reported...

24d ago

SLGL

Maintains Buy Rating and $184 Price Target on SGT-610’s Promising Gorlin Syndrome Opportunity

Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on Sol-Gel Technologies and keeping the price target...

27d ago

SLGL

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

WSW, NY, July 22nd, 2026, FinanceWire Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq:VRTX) agreed to pay...

2M ago

PTN

CRNX

Sol-Gel Technologies initiated with an Outperform at Mizuho

Mizuho initiated coverage of Sol-Gel Technologies (SLGL) with an Outperform rating and $285 price target The firm sees...

3M ago

SLGL

Sol-Gel Technologies initiated with a Buy at TD Cowen

TD Cowen analyst Stacy Ku initiated coverage of Sol-Gel Technologies (SLGL) with a Buy rating and no price...

4M ago

SLGL

Analyst Maintains Buy on Sol-Gel, Citing SGT-610 Progress and Solid Cash Runway with Unchanged $184 Price Target

Sol-Gel Technologies, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Dolezal from...

4M ago

SLGL

Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year

Reports Q1 revenue $108,000 vs. $1.03M last year. Mori Arkin, executive chairman of Sol-Gel, stated: “The first quarter...

4M ago

SLGL

Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering

Sol-Gel Technologies ( ($SLGL) ) just unveiled an announcement. In the first quarter of 2026, Sol-Gel Technologies secured...

4M ago

SLGL

Sol-Gel Technologies Prices $33.1 Million Oversubscribed Equity Offering to Advance SGT-610

Sol-Gel Technologies ( ($SLGL) ) has provided an update. On March 23, 2026, Sol-Gel Technologies entered into an...

6M ago

SLGL

Sol-Gel Technologies 459K share Spot Secondary priced at $72.00

TD Cowen and LifeSci Capital are acting as joint book running managers for the offering. Published first on...

6M ago

SLGL

Sol Gel Technologies trading resumes

09:48 EDT Sol Gel Technologies trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

6M ago

SLGL

Sol Gel Technologies trading halted, volatility trading pause

09:38 EDT Sol Gel Technologies trading halted, volatility trading pause Published first on TheFly – the ultimate source...

6M ago

SLGL

Sol-Gel Technologies: Upside-Driven Buy on SGT-610’s Orphan Gorlin Syndrome Opportunity and Repriced Peak Sales Potential

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Sol-Gel Technologies, with...

8M ago

SLGL

4SG FAQ

What was Sol-Gel Technologies’s price range in the past 12 months?

Sol-Gel Technologies lowest stock price was €19.20 and its highest was €82.00 in the past 12 months.

What is Sol-Gel Technologies’s market cap?

Sol-Gel Technologies’s market cap is €186.05M.

When is Sol-Gel Technologies’s upcoming earnings report date?

Sol-Gel Technologies’s upcoming earnings report date is Nov 05, 2026 which is in 53 days.

How were Sol-Gel Technologies’s earnings last quarter?

Sol-Gel Technologies released its earnings results on Aug 20, 2026. The company reported -€0.974 earnings per share for the quarter, beating the consensus estimate of -€2.034 by €1.06.

Is Sol-Gel Technologies overvalued?

According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sol-Gel Technologies pay dividends?

Sol-Gel Technologies does not currently pay dividends.

What is Sol-Gel Technologies’s EPS estimate?

Sol-Gel Technologies’s EPS estimate is -1.9.

How many shares outstanding does Sol-Gel Technologies have?

Sol-Gel Technologies has 3,273,999 shares outstanding.

What happened to Sol-Gel Technologies’s price movement after its last earnings report?

Sol-Gel Technologies reported an EPS of -€0.974 in its last earnings report, beating expectations of -€2.034. Following the earnings report the stock price went down -1.504%.

Which hedge fund is a major shareholder of Sol-Gel Technologies?

Currently, no hedge funds are holding shares in DE:4SG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sol-Gel Technologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

36.76%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Sol-Gel Technologies

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

Sol-Gel Technologies (4SG) Earnings & Revenues

Historic Earnings Reports

4SG Stock 12 Month Forecast

Average Price Target

€169.49

▲(197.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","246":"€246","74.25":"€74.3","131.5":"€131.5","188.75":"€188.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":245.6140659,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€245.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":169.48806886666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€169.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.7984114,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€94.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,74.25,131.5,188.75,246],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58,72.43185122307692,86.86370244615385,101.29555366923077,115.7274048923077,130.1592561153846,144.59110733846154,159.02295856153847,173.4548097846154,187.8866610076923,202.31851223076924,216.75036345384618,231.18221467692308,{"y":245.6140659,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58,66.5760052974359,75.1520105948718,83.7280158923077,92.3040211897436,100.88002648717949,109.45603178461539,118.03203708205129,126.60804237948719,135.1840476769231,143.76005297435898,152.33605827179488,160.91206356923078,{"y":169.48806886666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58,60.83064703076923,63.66129406153846,66.4919410923077,69.32258812307693,72.15323515384615,74.98388218461538,77.81452921538462,80.64517624615385,83.47582327692308,86.30647030769231,89.13711733846154,91.96776436923076,{"y":94.7984114,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.7,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >